SEARCH RESULTS

Biotechnology in France

Rachid Boulaouine - 09-avr.-2014 06:56:48
Even though biotechnologies may be a recent sector of business activity, France has succeeded in developing real know-how  that is gaining international recognition. When it comes to biotechnologies, the French are cutting edge. According to Leeme, the federation of French medical companies, today France numbers 388 biotechs in the health field in France. Biotech France, another French association for biotech companies, indicates that a third of these companies have been in existence for over 10 years. Yet the number of creations in this field is exponential. To get an idea, 50 companies were started in 2012. Unheard of! Proof that there is a real entrepreneurial effervescence when it comes to this research in France. Young start-ups for the most part, French biotechs are mainly Small Medium sized companies. Only 4% of them have over 100 employees. On average, they employ 22 people. As to the type of activity, most of the French companies specialized in human sciences with therapeutic products are concentrated on cancer treatments. “The French have developed a full-fledged know-how on cardio-vascular devices, infectious diseases, dermatology, blood diseases and for surgery,” explains Yves Germani, Ubifrance’s manager for the health sector in North America. French enterprises don’t just do research; they discover! Altogether, the French biotech industry generated 261 Million Euros in turnover in 2011, compared with 186 Million in 2010. As for companies on the stock market, they generate 369 Million Euros in turnover. Concerning the pipeline, the expression used to indicate the number of molecules being developed, France is 4rth, behind the United Kingdom, Germany, Switzerland and Israel. Quite a solid ranking, but which should nevertheless be improved. When their results are examined in detail, we see that depending on the stage of development, French companies create more products in the pre-clinic phase, in other words, all those that have been carried out before the clinical trial with patients, which is completely logical. Between the start of development on a new medicine, a molecule and its release on the market can sometimes take up to 10 years. Unfortunately, the consequence of this is that a number of products fall by the wayside. To be noted, however, is one undeniable fact: since 2008, French companies have sold more and more products. To put it another way, as Yves Germani points out, French companies don’t just do research; they discover!” An increase of 63% in investment Even more impressive than all the rest, French biotech companies tend to have smaller R&D budgets than their European and international competitors. Fortunately, the culture of venture capital is developing very quickly in this sector. To give the general picture, the funds raised by French biotechs have increased by 63,1% from 2009 to 2012, reaching 178 Million Euros. Since the year 2000, they have managed to raise 2.920 Billion Euros. Today, French companies are naturally turning towards international opportunities to find new partners and new financial leverage. The proof is that such Small Medium companies as Affilogic, MedinCell, Interactive Biosoftware, Imabiotech or even O4CP all have one thing in common: they all are reaching out with confidence to mature markets like the United States, Canada and Western Europe.

FRENCH EXPERISE IN THE HEALTHCARE INDUSTRY IN JAKARTA

Rachid Boulaouine - 09-avr.-2014 06:37:26
  UBIFRANCE in Indonesia received a delegation of six French companies in the health sector from the 20 th to the 24 th of March 2014. This event gave the opportunity to our French companies to meet recognized and well-known players related to the health industry in Indonesia such as Siloam Hospital Group, Impression Body Care, Aneka Gas Industry, Telekom Indonesia and much more. BETEM INTERNATIONAL is a French engineering company with an expertise in clean room, and fire security engineering for hospitals. C2P HEALTHCARE offers Skin Breath, a high quality medical device to perform aesthetic and medical carboxytherapy treatments. DATEXIM commercializes a software platform for the storage, management and sharing of whole slide images. The included « full web » application has the advantage of being usable on every web browser supporting the HTML5 standards, without any third party software or plugin installation and on every operating system. GENEWAVE is developing GeneSpress which is an Automated Molecular Diagnostics Platform aiming at simultaneously testing a large numbers of markers. In less than four hours, these tests will be automatically made from a biological sample. LABORATOIRE PROTECSOM is a French high-technology company and offers performance valve holding chamber designed to optimize lung deposition of corticosteroids from HFA puffers. TLV HEALTHCARE is a French company that offers medical gas installation, bedhead and pendant systems.
About us
Business France is the national agency supporting the international development of the French economy, responsible for fostering export growth by French businesses, as well as promoting and facilitating international investment in France. It promotes France’s companies, business image and nationwide attractiveness as an investment location, and also runs the VIE international internship program. Founded on January 1, 2015 through a merger between UBIFRANCE and the Invest in France Agency, Business France has 1,500 personnel, both in France and in 70 countries throughout the world, who work with a network of public- and private-sector partners. Business France’s three missions are: - Fostering export growth by French businesses. - Promoting and facilitating international investment in France. - Promoting France’s companies, business image and nationwide attractiveness as an investment location.   These missions incl

READ MORE

    
    You Buy France 

    

    Vivapolis  

   

    Healthindustry

   

    Axema

Facebook
Press area & Media Gallery